Another implication of this announcement: The 510 k) application route for BTM is stated to be valid for "second degree burns, surgical wounds, partial and full thickness wounds, and other traumatic wounds". This list includes decubitus ulcers or bed sores, the condition for which the VAC dressing is being developed presently, also to be processed via the 510 k) pathway.
If NovoSkin's BTM is accepted for use in treating decubitus ulcers, any mode of treatment that involves changing dressings, with the associated risk of reinfection and other drawbacks, will be replaced by a new treatment paradigm utilizing an implanted biodegradable temporizing matrix, especially for more serious cases.
BTM treatment of decubitus ulcers will bring all its known benefits including rapid healing, low infection rates, superior resistance to scarring and skin contraction, and so on.
This is important as it could quickly develop into the largest early market for the BTM technology.
CZD Price at posting:
4.6¢ Sentiment: Buy Disclosure: Held
